Skip to main navigation Skip to main content
Home
Menu
  • Join Our Mailing List
  • Contact Us
  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search
 
Enter your keyword(s)

Breadcrumb

  1. BBCIC
  2. Resources
  3. FDA Guidance
  4. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product

Main navigation

  • About
    • About BBCIC
    • Governance
    • Partners
    • Contact
  • Research
  • News & Events
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search

Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product

Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product is the final version of a draft guidance for industry originally released in 2014. It is intended to assist sponsors with the design and use of clinical pharmacokinetic and pharmacodynamic studies to support a demonstration that a proposed therapeutic biological product is biosimilar to its reference product.

As explained in the guidance, clinical pharmacology studies play a critical role in the stepwise process for demonstrating biosimilarity. They may:

  • Support a demonstration that there are no clinically meaningful differences between a proposed biosimilar product and a reference product.
  • Address residual uncertainties that remain after the analytical evaluation.
  • Add to the totality of the evidence supporting a demonstration of biosimilarity.
  • Support a selective and targeted approach to the design of any recommended subsequent clinical studies.

The guidance discusses some of the overarching concepts related to clinical pharmacology testing for biosimilar products, approaches for developing the appropriate clinical pharmacology database, and the utility of modeling and simulation for designing clinical trials.

The full document is available on the FDA website.

Tags:

Why BBCIC?
Learn more about BBCIC and what we do.
Download Our Fact Sheet
Join BBCIC
Help us monitor use, impact, safety, and clinical effectiveness of biologics including biosimilars.
Participate in BBCIC

Contact Us

Send a Message

Address

675 N Washington Street
Suite 220
Alexandria, VA 22314

Phone

703.684.2600

Menu

  • About
  • Research
  • News & Events
  • Resources
  • Search
BBCIC Logo
  • Antitrust
  • Privacy Policy
  • Disclaimer


© 2023 Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)

  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search